Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Phase III Osteoporosis Study Is Company's Largest Clinical Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Clinical trials for Amgen's bone loss therapy AMG 162 will look at the entire spectrum of bone health, VP-R&D Perlmutter says. Phase II studies demonstrated lower incidence of dyspepsia and more rapid absorption than Fosamax, he says.

You may also be interested in...



Amgen Cites Osteoporosis Injectable’s Efficacy Over Fosamax In Study

Company presents preliminary Phase II results for AMG 162 that show a significantly greater total hip bone mineral density compared to Merck’s Fosamax; changes in lower spine BMD were comparable between the two agents. Amgen has initiated registration for a Phase III study.

Amgen Cites Osteoporosis Injectable’s Efficacy Over Fosamax In Study

Company presents preliminary Phase II results for AMG 162 that show a significantly greater total hip bone mineral density compared to Merck’s Fosamax; changes in lower spine BMD were comparable between the two agents. Amgen has initiated registration for a Phase III study.

Phase III Enrollment For Amgen's Panitumumab Slowed By Erbitux Approval

Enrollment in Amgen's U.S. Phase III trial for the colon cancer agent panitumumab has substantially slowed since the launch of Bristol-Myers Squibb/ImClone's Erbitux (cetuximab)

Related Content

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel